Cryoport, Inc. reported fourth‑quarter 2025 revenue of $45.45 million, surpassing the consensus estimate of roughly $42.9 million by about $2.5 million, a 5.8 % beat. The top‑line growth was driven by a 16 % year‑over‑year increase in Life Sciences Services revenue, which rose to $25.0 million, and a 29 % jump in commercial cell‑and‑gene‑therapy revenue, which reached $33.4 million.
The company posted a fourth‑quarter earnings‑per‑share loss of $0.27, missing the consensus estimate of $0.21 by $0.06, a 28.6 % miss. The miss was largely attributable to higher operating expenses and the impact of a one‑time charge related to restructuring costs, which offset the margin gains from the stronger mix.
Clinical‑trial support revenue grew 14 % YoY to $47.1 million, reflecting the company’s continued role in 760 global trials, about 70 % of the cell‑and‑gene‑therapy pipeline. The mix shift toward higher‑margin commercial services helped lift the consolidated gross margin to 47 % for the year, up from 44.4 % in 2024.
Adjusted EBITDA improved by $12 million year‑over‑year, driven by cost‑control initiatives and the expansion of high‑margin service contracts. The margin expansion to 47 % indicates that the company is successfully leveraging its scale to offset rising input costs.
Management left its full‑year 2026 revenue guidance unchanged at $190 million to $194 million, signaling confidence in continued demand for its services while acknowledging that profitability will remain a focus. The guidance reflects a moderate 8 % growth expectation, consistent with the company’s view of a stable market trajectory.
CEO Jerrell Shelton said, “2025 was a year of strong progress for Cryoport. We delivered full‑year revenue of $176.2 million, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets.” CFO Robert Stefanovich added, “We anticipate achieving positive adjusted EBITDA in the second half of 2026.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.